Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $25.4 million.

  • Zenas BioPharma's Non-Current Assets rose 16285.48% to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.9 million, marking a year-over-year change of. This contributed to the annual value of $14.0 million for FY2024, which is 6768.15% up from last year.
  • According to the latest figures from Q3 2025, Zenas BioPharma's Non-Current Assets is $25.4 million, which was up 16285.48% from $14.5 million recorded in Q2 2025.
  • Zenas BioPharma's Non-Current Assets' 5-year high stood at $25.4 million during Q3 2025, with a 5-year trough of $8.4 million in Q4 2023.
  • Over the past 3 years, Zenas BioPharma's median Non-Current Assets value was $14.3 million (recorded in 2024), while the average stood at $14.6 million.
  • Per our database at Business Quant, Zenas BioPharma's Non-Current Assets skyrocketed by 6768.15% in 2024 and then soared by 16285.48% in 2025.
  • Quarter analysis of 3 years shows Zenas BioPharma's Non-Current Assets stood at $8.4 million in 2023, then surged by 67.68% to $14.0 million in 2024, then soared by 80.68% to $25.4 million in 2025.
  • Its Non-Current Assets was $25.4 million in Q3 2025, compared to $14.5 million in Q2 2025 and $16.0 million in Q1 2025.